ALL libraries (COBIB.SI union bibliographic/catalogue database)
PDF
  • DPP-4 inhibitors in the prevention/treatment of pulmonary fibrosis, heart and kidney injury caused by covid-19-a therapeutic approach of choice in type 2 diabetic patients? [Elektronski vir]
    Smelcerović, Andrija ...
    Since the outbreak of SARS-CoV-2 virus more than 12,500,000 cases have been reported worldwide. Patients suffering from diabetes and other comorbidities are particularly susceptible to severe forms ... of the COVID-19, which might result in chronic complications following recovery. Dipeptidyl peptidase-4 inhibitors exert beneficial effects in prevention/treatment of pulmonary fibrosis, heart, and kidney injury, and since they may be a long-term consequence caused by COVID-19, it is reasonable to expect that DPP-4 inhibitors might be beneficial in alleviating long-term consequences of COVID-19. With that in mind, we would like to voice our concerns over chronic implications following recovery from COVID-19, especially not only in diabetic but also in non-diabetic patients, and to indicate that some preventive measures could be undertaken by application of DPP-4 inhibitors.
    Source: Frontiers in pharmacology [Elektronski vir]. - ISSN 1663-9812 (Vol. 11, 2020, str. 1-4)
    Type of material - e-article ; adult, serious
    Publish date - 2020
    Language - english
    COBISS.SI-ID - 25125123

    Link(s):

    https://www.frontiersin.org/articles/10.3389/fphar.2020.01185/full
    Repository of the University of Ljubljana – RUL
    DOI

Shelf entry